News and trends covered this week -- all about the latest policy and in practice implication for CRISPR -- include:
* California law requiring labels for self-editing kits (that don't exist yet)
* Alliance (including 13 of the most active companies in gene editing for therapeutics) statement against germline editing at this time -- and parallels/differences given China CRISPR babies scandal & recombinant DNA from 1970s
* clinical trials for CRISPR come of age, with first publicly identified patient (for sickle cell disease) and first study inside the human body (for inherited congenital blindness)
* CRISPR as a platform, applications, and what all of this means for innovation
Podden och tillhörande omslagsbild på den här sidan tillhör Andreessen Horowitz. Innehållet i podden är skapat av Andreessen Horowitz och inte av, eller tillsammans med, Poddtoppen.
